This company has been marked as potentially delisted and may not be actively trading. Cyclacel Pharmaceuticals (CYCCP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendHeadlinesTrendsBuy This Stock CYCCP vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Cyclacel Pharmaceuticals vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Cyclacel Pharmaceuticals (NASDAQ:CYCCP) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment. Does the media prefer ATNFW or CYCCP? In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Cyclacel Pharmaceuticals Neutral Is ATNFW or CYCCP more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Cyclacel Pharmaceuticals N/A N/A N/A Which has higher valuation & earnings, ATNFW or CYCCP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACyclacel PharmaceuticalsN/AN/AN/AN/AN/A SummaryCyclacel Pharmaceuticals beats 180 Life Sciences on 1 of the 1 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCCP vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$127.96M$5.56B$9.05BDividend Yield0.12%3.74%5.24%3.99%P/E RatioN/A3.4027.6520.23Price / SalesN/A4,084.30419.56119.26Price / CashN/A13.1926.2128.59Price / BookN/A42.828.035.65Net IncomeN/A-$92.79M$3.18B$249.15M Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCPCyclacel PharmaceuticalsN/A$6.25+17.9%N/A-27.3%$0.00N/A0.0012ATNFW180 Life SciencesN/A$0.01+7.5%N/A-6.9%$0.00N/A0.007Positive NewsGap DownSXTPW60 Degrees PharmaceuticalsN/A$0.06+11.5%N/A-17.4%$0.00$665.45K0.002Gap UpDRTSWAlpha Tau MedicalN/A$0.25+2.9%N/A+5.5%$0.00N/A0.0080News CoveragePositive NewsWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.04-19.2%N/AN/A$0.00N/A0.0059Positive NewsBCTXWBriaCell TherapeuticsN/A$0.07-2.4%N/A-70.6%$0.00N/A0.008Gap DownCDIOWCardio DiagnosticsN/A$0.02+9.5%N/A-59.5%$0.00$19.90K0.007Gap DownCTCXWCarmellN/A$0.03+6.8%N/A-63.2%$0.00$32.84K0.0014Gap UpCELUWCelularityN/A$0.05+7.4%N/A+100.0%$0.00$54.22M0.00220Positive NewsGap DownCEROWCERo TherapeuticsN/A$0.02-13.9%N/A+25.0%$0.00N/A0.008Positive NewsGap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Anew Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Carmell Competitors Celularity Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCCP) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
